Literature DB >> 31575617

How Does CREDENCE Inform Best Use of SGLT2 Inhibitors in CKD?

Joshua J Neumiller1, Rita R Kalyani2.   

Abstract

Entities:  

Keywords:  Canagliflozin; Hypoglycemic Agents; Sodium-Glucose Transporter 2; cardiovascular disease; cardiovascular outcomes; chronic kidney disease; chronic renal insufficiency; diabetes; end stage kidney disease; type 2 diabetes

Year:  2019        PMID： 31575617      PMCID： PMC6832045          DOI： 10.2215/CJN.05340419

Source DB:  PubMed          Journal:  Clin J Am Soc Nephrol        ISSN： 1555-9041            Impact factor:   8.237


× No keyword cloud information.
  10 in total

1.  Diabetic kidney disease: a report from an ADA Consensus Conference.

Authors:  Katherine R Tuttle; George L Bakris; Rudolf W Bilous; Jane L Chiang; Ian H de Boer; Jordi Goldstein-Fuchs; Irl B Hirsch; Kamyar Kalantar-Zadeh; Andrew S Narva; Sankar D Navaneethan; Joshua J Neumiller; Uptal D Patel; Robert E Ratner; Adam T Whaley-Connell; Mark E Molitch
Journal:  Am J Kidney Dis       Date:  2014-10       Impact factor: 8.860

2.  Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial.

Authors:  Ofri Mosenzon; Stephen D Wiviott; Avivit Cahn; Aliza Rozenberg; Ilan Yanuv; Erica L Goodrich; Sabina A Murphy; Hiddo J L Heerspink; Thomas A Zelniker; Jamie P Dwyer; Deepak L Bhatt; Lawrence A Leiter; Darren K McGuire; John P H Wilding; Eri T Kato; Ingrid A M Gause-Nilsson; Martin Fredriksson; Peter A Johansson; Anna Maria Langkilde; Marc S Sabatine; Itamar Raz
Journal:  Lancet Diabetes Endocrinol       Date:  2019-06-10       Impact factor: 32.069

3.  Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes.

Authors:  Stephen D Wiviott; Itamar Raz; Marc P Bonaca; Ofri Mosenzon; Eri T Kato; Avivit Cahn; Michael G Silverman; Thomas A Zelniker; Julia F Kuder; Sabina A Murphy; Deepak L Bhatt; Lawrence A Leiter; Darren K McGuire; John P H Wilding; Christian T Ruff; Ingrid A M Gause-Nilsson; Martin Fredriksson; Peter A Johansson; Anna-Maria Langkilde; Marc S Sabatine
Journal:  N Engl J Med       Date:  2018-11-10       Impact factor: 91.245

Review 4.  11. Microvascular Complications and Foot Care: Standards of Medical Care in Diabetes-2019.

Authors: 
Journal:  Diabetes Care       Date:  2019-01       Impact factor: 19.112

5.  Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.

Authors:  Bernard Zinman; Christoph Wanner; John M Lachin; David Fitchett; Erich Bluhmki; Stefan Hantel; Michaela Mattheus; Theresa Devins; Odd Erik Johansen; Hans J Woerle; Uli C Broedl; Silvio E Inzucchi
Journal:  N Engl J Med       Date:  2015-09-17       Impact factor: 91.245

6.  Diabetic Kidney Disease: Challenges, Progress, and Possibilities.

Authors:  Radica Z Alicic; Michele T Rooney; Katherine R Tuttle
Journal:  Clin J Am Soc Nephrol       Date:  2017-05-18       Impact factor: 8.237

7.  Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.

Authors:  Bruce Neal; Vlado Perkovic; Kenneth W Mahaffey; Dick de Zeeuw; Greg Fulcher; Ngozi Erondu; Wayne Shaw; Gordon Law; Mehul Desai; David R Matthews
Journal:  N Engl J Med       Date:  2017-06-12       Impact factor: 91.245

8.  Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy.

Authors:  Vlado Perkovic; Meg J Jardine; Bruce Neal; Severine Bompoint; Hiddo J L Heerspink; David M Charytan; Robert Edwards; Rajiv Agarwal; George Bakris; Scott Bull; Christopher P Cannon; George Capuano; Pei-Ling Chu; Dick de Zeeuw; Tom Greene; Adeera Levin; Carol Pollock; David C Wheeler; Yshai Yavin; Hong Zhang; Bernard Zinman; Gary Meininger; Barry M Brenner; Kenneth W Mahaffey
Journal:  N Engl J Med       Date:  2019-04-14       Impact factor: 91.245

9.  Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes.

Authors:  Christoph Wanner; Silvio E Inzucchi; John M Lachin; David Fitchett; Maximilian von Eynatten; Michaela Mattheus; Odd Erik Johansen; Hans J Woerle; Uli C Broedl; Bernard Zinman
Journal:  N Engl J Med       Date:  2016-06-14       Impact factor: 91.245

Review 10.  Sodium-Glucose Cotransporter 2 Inhibition and Diabetic Kidney Disease.

Authors:  Radica Z Alicic; Joshua J Neumiller; Emily J Johnson; Brad Dieter; Katherine R Tuttle
Journal:  Diabetes       Date:  2019-02       Impact factor: 9.461
  10 in total
  3 in total

Review 1.  SGLT2 Inhibitors: Emerging Roles in the Protection Against Cardiovascular and Kidney Disease Among Diabetic Patients.

Authors:  George Vasquez-Rios; Girish N Nadkarni
Journal:  Int J Nephrol Renovasc Dis       Date:  2020-10-28

Review 2.  Dedicated kidney disease-focused outcome trials with sodium-glucose cotransporter-2 inhibitors: Lessons from CREDENCE and expectations from DAPA-HF, DAPA-CKD, and EMPA-KIDNEY.

Authors:  Jinnie J Rhee; Meg J Jardine; Glenn M Chertow; Kenneth W Mahaffey
Journal:  Diabetes Obes Metab       Date:  2020-04       Impact factor: 6.577

Review 3.  Potential Safety Issues with Use of Sodium-Glucose Cotransporter 2 Inhibitors, Particularly in People with Type 2 Diabetes and Chronic Kidney Disease.

Authors:  Tamara Y Milder; Sophie L Stocker; Richard O Day; Jerry R Greenfield
Journal:  Drug Saf       Date:  2020-10-23       Impact factor: 5.606
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.